Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | FBP1 | P09467 | 4/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6802725 | 0.76 | KMT2A (0.66) | MEN1TSHRKMT2AHTTSMN1; SMN2 | |
| SCHEMBL6800094 | 0.73 | — | — | |
| SCHEMBL7562968 | 0.69 | CDK1 (0.44) | TSHRHTTSMN1; SMN2CYP3A4CYP2C19 | |
| SCHEMBL7562558 | 0.64 | CYP2C19 (0.32) | TSHRKMT2ASMN1; SMN2CYP3A4CYP2C19 | |
| SCHEMBL10960588 | 0.62 | EPHX1 (0.58) | TSHREPHX1ALDH1A1 | |
| SCHEMBL10960416 | 0.62 | EPHX1 (0.58) | TSHREPHX1ALDH1A1 | |
| SCHEMBL10962041 | 0.62 | EPHX1 (0.58) | TSHREPHX1ALDH1A1 | |
| SCHEMBL1272676 | 0.62 | EPHX1 (0.58) | TSHREPHX1ALDH1A1 | |
| SCHEMBL1273855 | 0.62 | EPHX1 (0.58) | TSHREPHX1ALDH1A1 | |
| SCHEMBL22622093 | 0.62 | EPHX1 (0.58) | TSHREPHX1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040010142-A1 | Novel process | NOVO NORDISK A/S (DK) | 2004-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040010142-A1 | Novel process | UGT1A1, CYP4X1, CYP4B1 | MEN1 967/4885TSHR 3865/4885KMT2A 4646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.